Salix Pharmaceuticals, Ltd. Provides Updates On Wholesaler Inventory Reductions And The XIFAXAN® 550 For IBS-D Approval Timeline, And Provides Preliminary Guidance For 2015 And 2016

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix” or the “Company”) today announced that it is working cooperatively with its principal pharmaceutical wholesalers to accelerate the reduction of wholesaler inventory levels of XIFAXAN® 550, APRISO® and UCERIS® to the Company’s target of approximately three months by the end of 2015 – one year earlier than previously announced.

Help employers find you! Check out all the jobs and post your resume.